STAAR Surgical Company (STAA)
After hours:
| Previous Close | 46.55 |
| Open | 46.50 |
| Bid | 47.99 x 100 |
| Ask | 48.37 x 200 |
| Day's Range | 45.87 - 48.50 |
| 52 Week Range | 26.66 - 73.13 |
| Volume | |
| Avg. Volume | 721,606 |
| Market Cap | 2.355B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 112.07 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
LAKE FOREST, Calif., April 04, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company
- Business Wire
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
LAKE FOREST, Calif., April 02, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the company
- PR Newswire
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
